依普利酮对HIV感染者动脉炎症的影响:MIRABELLA HIV研究
MIRABELLA HIV 子研究纳入26例接受良好治疗、无已知心血管疾病的HIV感染者,随机接受依普利酮50 mg每日两次或安慰剂治疗12个月,采用18F-FDG PET/CT评估动脉炎症。结果显示依普利酮组索引血管靶本比(TBR)较安慰剂组显著降低,且TBR下降与负荷心肌血流改善相关。
要点
- 索引血管最病变段TBR和颈动脉索引血管TBR也见显著下降。
核心结论
- 在接受良好治疗且无已知心血管疾病的HIV感染者中,依普利酮与动脉炎症降低相关。
- 18F-FDG PET/CT所测动脉炎症的降低与负荷心肌灌注改善相关。
研究设计与样本
- MIRABELLA HIV是MIRACLE HIV研究的子研究,为双盲、安慰剂对照随机临床试验。
- 纳入2017年2月至2022年3月期间接受良好治疗、无已知心血管疾病且当前未使用他汀的HIV感染者。
- 共26例参与者随机接受依普利酮50 mg每日两次(13例)或安慰剂(13例),治疗12个月。
- 采用18F-FDG PET/CT评估主动脉和颈动脉的动脉炎症。
临床怎么用
- 对于接受良好治疗且无已知心血管疾病的HIV感染者,依普利酮可能作为减轻动脉炎症的潜在治疗策略。
- 需进一步开展更大规模研究验证依普利酮对炎症介导心血管疾病的疗效。
局限性
- 本研究样本量小(共26例参与者)。
- 研究仅纳入当前未使用他汀的HIV感染者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The risk for atherosclerotic disease is increased 1.5- to 2.0-fold among persons with HIV (PWH). Increased activation of the renin-angiotensin-aldosterone system may contribute to increased arterial inflammation in this population. OBJECTIVE: To determine the effects of eplerenone on arterial inflammation among well-treated PWH without known cardiovascular disease (CVD). DESIGN, SETTING, AND PARTICIPANTS: Well-treated PWH who participated in the double-blinded, placebo-controlled, Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV (MIRACLE HIV) study between February 2017 and March 2022 assessing the effects of eplerenone on myocardial perfusion were invited to participate in the Mineralocorticoid Receptor Antagonism By Eplerenone to Lower Arterial Inflammation in HIV (MIRABELLA) substudy if there was no current statin use. Participants were enrolled in the MIRABELLA study and underwent additional 18F-fludeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) imaging of the aorta and carotid arteries to assess arterial inflammation over 12 months of treatment with eplerenone vs placebo. INTERVENTIONS: Eplerenone, 50 mg, twice a day vs identical placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was change in target to background ratio (TBR), a measure of arterial wall inflammation, in the index vessel after 12 months of treatment. The index vessel was defined as the vessel (aorta, left carotid artery, or right carotid artery) with the highest TBR at baseline in each participant. RESULTS: A total of 26 participants (mean [SD] age, 54 [7] years; 18 male [69%]) were enrolled in the study. Treatment groups (eplerenone, 13 vs placebo, 13) were of similar age, sex, and body mass index. Eplerenone was associated with a reduction in TBR of the primary end point, the index vessel (eplerenone vs placebo: model treatment effect, -0.31; 95% CI, -0.50 to -0.11; P = .006; percentage change, -12.4% [IQR, -21.9% to -2.6%] vs 5.1% [IQR, -1.6% to 11.0%]; P = .003). We further observed a significant reduction of the TBR of the most diseased segment (MDS) of the index vessel (eplerenone vs placebo: -19.1% [IQR, -27.0% to -11.9%] vs 6.8% [IQR, -9.1% to 12.1%]; P = .007). A similar result was seen assessing the index vessel of the carotids (eplerenone vs placebo: -10.0% [IQR, -21.8% to 3.6%] vs 9.7% [IQR, -9.8% to 15.9%]; P = .046). Reduction in the TBR of MDS of the index vessel on 18F-FDG PET/CT correlated with improvement in the stress myocardial blood flow on cardiac magnetic resonance imaging (Spearman ρ = -0.67; P = .01). CONCLUSION AND RELEVANCE: In this small randomized clinical trial, eplerenone was associated with reduction in arterial inflammation among well-treated PWH without known CVD. In addition, reductions in arterial inflammation as measured by 18F-FDG PET/CT were related to improvements in stress myocardial perfusion. Further larger studies should explore whether eplerenone is a potential treatment strategy for inflammatory-mediated CVD in PWH. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02740179.
引用
- Srinivasa S, Abohashem S, Walpert AR, et al. Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV: The MIRABELLA HIV Study. JAMA Cardiol. 2024. PMID: 38090987. doi:10.1001/jamacardio.2023.4578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。